Cosmo Technologies
As of the edition of 20 October 2026, Cosmo Technologies runs 3 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Status not established | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methylene blue cation | Ends 2027 (exclusivity) | 1 |
| Rifamycin | Ends 2028 (exclusivity) | 0 |
A route B row is one company at one target.